Metropolis Healthcare Limited reported robust financial results for the fiscal year ended March 31, 2026 (FY26), with consolidated revenue from operations increasing by 24% to ₹1,646 crore. Profit After Tax (PAT) surged by 31% to ₹191 crore, reflecting improved operating leverage and disciplined cost management. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 32% to ₹401 crore, expanding the EBITDA margin to 24.4% from high single digits in the prior year.

The financial strength was driven by broad-based growth across consumer and institutional segments. On an organic basis, patient volumes increased by 7.5% to 13.5 million, while test volumes grew by 8.0% to 28.4 million. Revenue per patient improved by 6%, indicating a shift towards higher-value testing. Organic Business-to-Consumer (B2C) revenue rose by 14%, and Business-to-Business (B2B) revenue increased by 13%. Specialty Diagnostics and TruHealth segments recorded organic growth of 16% and 21%, respectively, reinforcing the company's premiumisation strategy.

Key Financial Metrics

Operational expansion played a critical role in the year's performance. Metropolis added approximately 490 service centres, bringing its total network to over 5,000 touchpoints across more than 750 towns. The company successfully integrated four acquisitions during the year: Core Diagnostics, Scientific Pathology, Dr Ahujas’ Pathology and Imaging Centre (DAPIC), and Ambika Pathology. These acquired businesses contributed approximately 8% of Group revenue and increased North India's share of the business from 8% to 17%. Core Diagnostics emerged as a strategic platform for oncology and genomics, exiting the year with high single-digit EBITDA margins.

Strategic Developments and Shareholder Returns

In March 2026, the company issued bonus shares in a 3:1 ratio, capitalising approximately ₹31.10 crore from the securities premium account to enhance liquidity and broaden the shareholder base. The Board declared first and second interim dividends of ₹4 and ₹1 per equity share, respectively, for FY26. No final dividend was recommended.

The company also transferred its External Quality Assessment Services (EQAS) business to its wholly-owned subsidiary, Metropolis Quality Solutions Private Limited, for a consideration of up to ₹1.25 crore. This restructuring aims to enable the EQAS business to operate as an independent unit with dedicated management resources.

What the Numbers Show

The divergence between reported PAT growth (31%) and the previous year's normalised figures highlights the impact of one-off expenses in FY25. The prior year included approximately ₹21 crore in acquisition-related costs and legal fees, which suppressed comparables. Excluding these items, the underlying operational improvement is evident in the EBITDA margin expansion to 24.4%. Furthermore, the significant contribution from recently acquired entities (8% of revenue) demonstrates the effectiveness of the company's integration playbook, where year one focuses on synergy capture. The rise in revenue per patient by 6% suggests that growth is not solely volume-driven but also benefits from a richer mix of specialty and preventive healthcare tests.

Metropolis Healthcare Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange and National Stock Exchange on July 27, 2026. The filing, mandated under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outlines the company’s progress on environmental stewardship, social responsibility, and governance frameworks. For FY26, the company reported a turnover of ₹1,36,547.17 lakh and a net worth of ₹1,38,910.53 lakh, reinforcing its scale as it pursues long-term sustainability goals including net-zero emissions by FY2043.

The report details significant strides in renewable energy adoption, with approximately 30% of electricity at the Metropolis Global Reference Laboratory sourced from renewables. The company has initiated a 100kW rooftop solar programme across select facilities and aims to source ~50% of its electricity from renewable sources by FY2030. Additionally, Metropolis targets a 45% reduction in greenhouse gas emissions intensity by FY2030 and a 30% reduction in water intensity by FY2043. These environmental commitments are supported by infrastructure upgrades, including LED lighting retrofits and HVAC optimization.

Workforce Diversity and Social Impact

On the social front, Metropolis reported that women constitute approximately 44% of its overall workforce, progressing toward its goal of a 50:50 gender-balanced workforce by FY2028. The company maintains a Net Promoter Score (NPS) of 87, reflecting customer satisfaction. Its Corporate Social Responsibility (CSR) initiatives reached over 13 lakh beneficiaries through the Adolescent Reproductive and Sexual Health (ARSH) programme and preventive healthcare campaigns. In FY26, the company spent ₹56,08,255 on CSR projects in designated aspirational districts across multiple states.

Operational Footprint and Governance

Metropolis operates 212 laboratories nationally and five offices internationally, serving markets in Kenya, Zambia, Ghana, Tanzania, and Uganda, alongside B2B clients in 16 other countries. Exports contributed 3.31% to total turnover. The company maintains ISO 27001 and ISO 27701 certifications for information security and privacy, with no data breaches reported during the year. The CSR & ESG Committee, chaired by Chairperson & Whole-time Director Ameera Shah, oversees these sustainability efforts.

Key Financial and Operational Metrics

What the Numbers Show

The integration of sustainability into core operations is evident in Metropolis’s shift toward renewable energy and digital efficiency. With exports accounting for only 3.31% of turnover, the company’s primary growth and sustainability impact remain domestic, where it manages a dense network of 212 labs. The high NPS of 87 suggests that operational enhancements, such as the 'Go Digital, Go Green' initiative which reduces paper usage, are positively influencing customer experience without compromising service quality. The commitment to zero waste to landfill by FY2030 indicates a strategic focus on waste management, critical for a diagnostic service provider handling biomedical waste.